Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients

OBJECTIVE: This study aimed to explore the cost-effectiveness of etanercept plus methotrexate (ETN+MTX) compared to triple disease-modifying anti-rheumatic drugs (DMARDs) in treating Chinese rheumatoid arthritis (RA) patients. METHODS: The 134 Chinese RA patients who were about to initiate ETN+MTX o...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zhi-Chao, Fei, Hong-Ping, Wang, Zhi-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
6900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220444/
https://www.ncbi.nlm.nih.gov/pubmed/32011430
http://dx.doi.org/10.1097/MD.0000000000016635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220444/
https://www.ncbi.nlm.nih.gov/pubmed/32011430
http://dx.doi.org/10.1097/MD.0000000000016635

Ejemplares similares